Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Atorvastatin Calcium

FDA-approved product (tablet, oral), marketed as Atorvaliq, Atorvastatin Calcium, Lipitor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Atorvastatin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormal circulating lipid concentration
  • Acute myocardial infarction
  • Angina pectoris
  • Cardiovascular disease
  • Congestive heart failure
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Heart failure
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Atorvastatin Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Atorvastatin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome

    NCT07799779 · start 2026-09

    Registered record
    Registry ID
    NCT07799779
    Conditions
    Acute Coronary Syndromes (ACS)
    Interventions
    Inclisiran; Atorvastatin or Rosuvastatin; Ezetimibe
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-09
    Enrolment
    294

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndromes (ACS)
    InterventionInclisiran; Atorvastatin or Rosuvastatin; Ezetimibe
    PhasePhase 4
    Registry statusNot yet recruiting

  • Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity

    NCT07785934 · start 2026-05-27

    Registered record
    Registry ID
    NCT07785934
    Conditions
    Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics
    Interventions
    UBT251; Metformin hydrochloride; Warfarin Sodium; Atorvastatin calcium; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-27
    Completion
    2026-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics
    InterventionUBT251; Metformin hydrochloride; Warfarin Sodium; Atorvastatin calcium +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

    NCT07359105 · start 2026-03-09

    Registered record
    Registry ID
    NCT07359105
    Conditions
    Dyslipidemia Associated With Type II Diabetes Mellitus
    Interventions
    Moderate-intensity statin monotherapy; Ezetimibe or ezetimibe-statin combination therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-03-09
    Completion
    2029-12-31
    Enrolment
    2,186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia Associated With Type II Diabetes Mellitus
    InterventionModerate-intensity statin monotherapy; Ezetimibe or ezetimibe-statin combination therapy
    PhaseNot applicable
    Registry statusRecruiting

  • Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis

    NCT06764966 · start 2025-09-09

    Registered record
    Registry ID
    NCT06764966
    Conditions
    Decompensated Liver Cirrhosis; Cirrhosis; Decompensated Cirrhosis of Liver; Decompensated Cirrhosis and Ascites
    Interventions
    Atorvastatin 20 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-09
    Completion
    2027-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDecompensated Liver Cirrhosis; Cirrhosis; Decompensated Cirrhosis of Liver; Decompensated Cirrhosis and Ascites
    InterventionAtorvastatin 20 mg; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Atorvastatin Plus Escitalopram for Depression With Dyslipidemia

    NCT07712367 · start 2025-09-01

    Registered record
    Registry ID
    NCT07712367
    Conditions
    Depressive Episode, Dyslipidemia
    Interventions
    Escitalopram plus atorvastatin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-09-01
    Completion
    2026-05-27
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Episode, Dyslipidemia
    InterventionEscitalopram plus atorvastatin
    PhaseNot recorded
    Registry statusCompleted

  • Systems Biological Assessment of Statin Effect on Vaccine Responses

    NCT06024096 · start 2023-09-20

    Registered record
    Registry ID
    NCT06024096
    Conditions
    Vaccine Response
    Interventions
    Atorvastatin; Quadrivalent seasonal influenza vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-09-20
    Completion
    2024-12-16
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaccine Response
    InterventionAtorvastatin; Quadrivalent seasonal influenza vaccine
    PhasePhase 4
    Registry statusCompleted

  • High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study

    NCT05585151 · start 2022-11-09

    Registered record
    Registry ID
    NCT05585151
    Conditions
    Cerebral Atherosclerosis
    Interventions
    Evolocumab 140 MG/ML; Intensive statin treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-11-09
    Completion
    2024-10-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Atherosclerosis
    InterventionEvolocumab 140 MG/ML; Intensive statin treatment
    PhasePhase 4
    Registry statusUnknown

  • Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT

    NCT04952350 · start 2021-08-14

    Registered record
    Registry ID
    NCT04952350
    Conditions
    Covid19; SARS-CoV2 Infection; COVID-19 Pneumonia
    Interventions
    Atorvastatin 40 Mg Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-08-14
    Completion
    2022-04
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-CoV2 Infection; COVID-19 Pneumonia
    InterventionAtorvastatin 40 Mg Oral Tablet; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients

    NCT05395143 · start 2021-05-01

    Registered record
    Registry ID
    NCT05395143
    Conditions
    Hyperlipidemias
    Interventions
    Zinc sulfate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-05-01
    Completion
    2022-07-10
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemias
    InterventionZinc sulfate; Placebo
    PhasePhase 2
    Registry statusUnknown

  • A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia

    NCT04455581 · start 2020-09-01

    Registered record
    Registry ID
    NCT04455581
    Conditions
    Familial Hypercholesterolemia
    Interventions
    SHR-1209
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2021-08-31
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Hypercholesterolemia
    InterventionSHR-1209
    PhasePhase 2
    Registry statusUnknown

  • CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

    NCT04369664 · start 2020-08-12

    Registered record
    Registry ID
    NCT04369664
    Conditions
    Type 2 Diabetes
    Interventions
    Statin; PCSK9 inhibitor; Ezetimibe 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-08-12
    Completion
    2023-10-19
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionStatin; PCSK9 inhibitor; Ezetimibe 10mg
    PhasePhase 4
    Registry statusCompleted

  • High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study

    NCT03188978 · start 2018-11-01

    Registered record
    Registry ID
    NCT03188978
    Conditions
    Primary Arteriovenous Fistula Failure
    Interventions
    Atorvastatin 40mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-11-01
    Completion
    2019-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Arteriovenous Fistula Failure
    InterventionAtorvastatin 40mg; Placebo
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Phase I Drug-drug Interaction of Omega-3 and Atorvastatin

    NCT03438955 · start 2018-02-01

    Registered record
    Registry ID
    NCT03438955
    Conditions
    Hyperlipidemia, Hypertriglyceridemia
    Interventions
    Omacor; Pritor; Omacor + Pritor; Pritor + Omacor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2018-02-01
    Completion
    2018-08-31
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia, Hypertriglyceridemia
    InterventionOmacor; Pritor; Omacor + Pritor; Pritor + Omacor
    PhasePhase 1
    Registry statusUnknown

  • Type 2 Diabetic Patients Maintained on Statin Therapy

    NCT03784703 · start 2018-01-01

    Registered record
    Registry ID
    NCT03784703
    Conditions
    Dyslipidemia Associated With Type II Diabetes Mellitus
    Interventions
    Atorvastatin 40 Mg Oral Tablet; Rosuvastatin 10 Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2020-01-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia Associated With Type II Diabetes Mellitus
    InterventionAtorvastatin 40 Mg Oral Tablet; Rosuvastatin 10 Mg Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Subclinical Cardiovascular Disease in Psoriatic Disease

    NCT03228017 · start 2017-08-01

    Registered record
    Registry ID
    NCT03228017
    Conditions
    Cardiovascular Diseases; Myocardial Infarction; Atherosclerotic Cardiovascular Disease; Thrombotic Vascular Disease
    Interventions
    Aspirin and/or Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-08-01
    Completion
    2019-04-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Myocardial Infarction; Atherosclerotic Cardiovascular Disease; Thrombotic Vascular Disease
    InterventionAspirin and/or Atorvastatin
    PhasePhase 4
    Registry statusCompleted